This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Comment

. 2018 Jul 5;379(1):91-2.

doi: 10.1056/NEJMc1805988.

Immune Checkpoint Blockade in Advanced Renal-Cell Carcinoma

Matteo Santoni^{1

2}, Rodolfo Montironi³, Nicola Battelli¹

Affiliations

Affiliations

¹ Macerata Hospital, Macerata, Italy
² mattymo@alice.it
³ Polytechnic University of the Marche Region, Ancona, Italy

PMID: 29975027
DOI: 10.1056/NEJMc1805988

Comment

Immune Checkpoint Blockade in Advanced Renal-Cell Carcinoma

Matteo Santoni et al. N Engl J Med. 2018.

. 2018 Jul 5;379(1):91-2.

doi: 10.1056/NEJMc1805988.

Authors

Matteo Santoni^{1

2}, Rodolfo Montironi³, Nicola Battelli¹

Affiliations

¹ Macerata Hospital, Macerata, Italy
² mattymo@alice.it
³ Polytechnic University of the Marche Region, Ancona, Italy

PMID: 29975027
DOI: 10.1056/NEJMc1805988

No abstract available

PubMed Disclaimer

Comment in

Immune Checkpoint Blockade in Advanced Renal-Cell Carcinoma.
Motzer RJ, McHenry MB, Chen AC. Motzer RJ, et al. N Engl J Med. 2018 Jul 5;379(1):92-93. doi: 10.1056/NEJMc1805988. N Engl J Med. 2018. PMID: 29972749 No abstract available.

Comment on

Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma.
Motzer RJ, Tannir NM, McDermott DF, Arén Frontera O, Melichar B, Choueiri TK, Plimack ER, Barthélémy P, Porta C, George S, Powles T, Donskov F, Neiman V, Kollmannsberger CK, Salman P, Gurney H, Hawkins R, Ravaud A, Grimm MO, Bracarda S, Barrios CH, Tomita Y, Castellano D, Rini BI, Chen AC, Mekan S, McHenry MB, Wind-Rotolo M, Doan J, Sharma P, Hammers HJ, Escudier B; CheckMate 214 Investigators. Motzer RJ, et al. N Engl J Med. 2018 Apr 5;378(14):1277-1290. doi: 10.1056/NEJMoa1712126. Epub 2018 Mar 21. N Engl J Med. 2018. PMID: 29562145 Free PMC article. Clinical Trial.

Similar articles

Immune Checkpoint Blockade in Advanced Renal-Cell Carcinoma.
Motzer RJ, McHenry MB, Chen AC. Motzer RJ, et al. N Engl J Med. 2018 Jul 5;379(1):92-93. doi: 10.1056/NEJMc1805988. N Engl J Med. 2018. PMID: 29972749 No abstract available.
Progress and potential of immune checkpoint blockade for treating advanced renal cell carcinoma.
Tykodi SS. Tykodi SS. Immunotherapy. 2013 Jun;5(6):607-19. doi: 10.2217/imt.13.39. Immunotherapy. 2013. PMID: 23725284 Review.
Immune Checkpoint Therapy in Renal Cell Carcinoma.
Lee CH, Motzer RJ. Lee CH, et al. Cancer J. 2016 Mar-Apr;22(2):92-5. doi: 10.1097/PPO.0000000000000177. Cancer J. 2016. PMID: 27111903 Review.
Immune checkpoint blockade as a novel immunotherapeutic strategy for renal cell carcinoma: a review of clinical trials.
Godwin JL, Zibelman M, Plimack ER, Geynisman DM. Godwin JL, et al. Discov Med. 2014 Dec;18(101):341-50. Discov Med. 2014. PMID: 25549705 Review.
Checkpoint Inhibitors for the Treatment of Renal Cell Carcinoma.
Ghatalia P, Zibelman M, Geynisman DM, Plimack ER. Ghatalia P, et al. Curr Treat Options Oncol. 2017 Jan;18(1):7. doi: 10.1007/s11864-017-0458-0. Curr Treat Options Oncol. 2017. PMID: 28210995 Review.

See all similar articles

Cited by

Benefits from standalone durvalumab treatment in an elderly patient with advanced prostatic sarcoma: a case report.
Wang L, Wang L, Hou D, Dong S, Wang A, Wang H. Wang L, et al. Transl Androl Urol. 2021 Nov;10(11):4298-4303. doi: 10.21037/tau-21-125. Transl Androl Urol. 2021. PMID: 34984194 Free PMC article.
Reinvigoration of cytotoxic T lymphocytes in microsatellite instability-high colon adenocarcinoma through lysosomal degradation of PD-L1.
Liu D, Yan J, Ma F, Wang J, Yan S, He W. Liu D, et al. Nat Commun. 2024 Aug 13;15(1):6922. doi: 10.1038/s41467-024-51386-7. Nat Commun. 2024. PMID: 39134545 Free PMC article.
Dysregulation of PD-L1 by UFMylation imparts tumor immune evasion and identified as a potential therapeutic target.
Zhou J, Ma X, He X, Chen B, Yuan J, Jin Z, Li L, Wang Z, Xiao Q, Cai Y, Zou Y, Cong YS. Zhou J, et al. Proc Natl Acad Sci U S A. 2023 Mar 14;120(11):e2215732120. doi: 10.1073/pnas.2215732120. Epub 2023 Mar 9. Proc Natl Acad Sci U S A. 2023. PMID: 36893266 Free PMC article.
A d-peptide-based oral nanotherapeutic modulates the PD-1/PD-L1 interaction for tumor immunotherapy.
Liu D, Wang J, You W, Ma F, Sun Q, She J, He W, Yang G. Liu D, et al. Front Immunol. 2023 Jul 17;14:1228581. doi: 10.3389/fimmu.2023.1228581. eCollection 2023. Front Immunol. 2023. PMID: 37529049 Free PMC article.

Publication types

Actions
Actions

MeSH terms

Actions
Actions
Actions

LinkOut - more resources

Full Text Sources
- Atypon
- Ovid Technologies, Inc.
Other Literature Sources
- scite Smart Citations
Medical
- MedlinePlus Health Information